Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review.
- 2012-05-02
- Systematic Review · n = 2,008
- BJU international 109(12)
- Roderick MacDonald
- James W Tacklind
- Indulis Rutks
- Timothy J Wilt
- PubMed: 22551330
- DOI: 10.1111/j.1464-410x.2012.11172.x
- High evidence
- Clinical
proportions of clinical responders (≥ 3 point decrease in the AUASI) were nearly identical (43% vs 44% for Serenoa repens and placebo, respectively) with a corresponding risk ratio of 0.96 (95% CI 0.76-1.22)
- Effect
- Neutral
- Effect size
- Small
- Significant
- No
- Dose
- double and triple doses (640 mg/day, 960 mg/day)